Our data suggest that tryptophan metabolism is dysregulated in ADPKD and that its inhibition results in changes to the CME and slows disease progression, making IDO1 a therapeutic target for ADPKD. This evidence concerns the gene IDO1 and autosomal dominant polycystic kidney disease.